We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M Turnover 44.83%
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
-1.01%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$4.36B
AUM Growth
-$447M
Cap. Flow
+$100M
Cap. Flow %
2.31%
Top 10 Hldgs %
45.02%
Holding
102
New
10
Increased
31
Reduced
13
Closed
20
Avg Time Held Equity + Options
0.9 years
Top 10 Avg Time Held Equity + Options
0.3 years
Top 20 Avg Time Held Equity + Options
0.6 years
Avg Time Held Equity only
0.9 years
Top 10 Avg Time Held Equity only
0.3 years
Top 20 Avg Time Held Equity only
0.6 years

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$183M
2
ARGX icon
argenx
ARGX
+$128M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$108M
4
JNJ icon
Johnson & Johnson
JNJ
+$97.3M
5
HUM icon
Humana
HUM
+$95M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$194M
2
BAX icon
Baxter International
BAX
+$149M
3
BHVN icon
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$146M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$115M
5
ABBV icon
AbbVie
ABBV
+$109M

Sector Composition

Rank Sector Weight
1 Healthcare 95.61%
2 Miscellaneous 3.74%
3 Financials 0.54%
4 Technology 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
AZN icon
1
AstraZeneca
AZN
$259B
$231M 5.31%
1,749,500
-100,500
-5% -$13.2M
2021 Q3
3 quarters
VRTX icon
2
Vertex Pharmaceuticals
VRTX
$129B
$223M 5.13%
793,000
+247,400
+45% +$66.2M
2020 Q4
6 quarters
ARGX icon
3
argenx
ARGX
$53.2B
$217M 4.98%
572,500
+396,500
+225% +$128M
2022 Q1
1 quarter
ELV icon
4
Elevance Health
ELV
$92.9B
$213M 4.89%
441,000
+41,600
+10% +$20.6M
2021 Q4
2 quarters
AVTR icon
5
Avantor
AVTR
$10.9B
$207M 4.75%
6,652,700
+984,400
+17% +$30.7M
2020 Q2
8 quarters
LLY icon
6
Eli Lilly
LLY
$1.12T
$198M 4.54%
+610,000
New +$183M
2022 Q2
0 quarters
HUM icon
7
Humana
HUM
$51.9B
$193M 4.43%
412,300
+213,400
+107% +$95M
2022 Q1
1 quarter
UTHR icon
8
United Therapeutics
UTHR
$23.2B
$171M 3.93%
725,600
+6,654
+0.9% +$1.35M
2021 Q2
4 quarters
JNJ icon
9
Johnson & Johnson
JNJ
$610B
$160M 3.67%
900,200
+546,200
+154% +$97.3M
2022 Q1
1 quarter
HZNP
10
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$148M 3.4%
1,856,900
+725,500
+64% +$68.7M
2019 Q4
10 quarters
NBIX icon
11
Neurocrine Biosciences
NBIX
$13.9B
$143M 3.28%
1,467,600
+307,600
+27% +$28.4M
2020 Q4
6 quarters
ARVN icon
12
Arvinas
ARVN
$468M
$141M 3.24%
3,355,623
+440,323
+15% +$22.1M
2020 Q2
8 quarters
XBI icon
13
State Street SPDR S&P Biotech ETF
XBI
$9.9B
$139M 3.2%
1,875,000
+1,435,000
+326% +$108M
2022 Q1
1 quarter
MCK icon
14
McKesson
MCK
$116B
$127M 2.91%
388,800
+199,300
+105% +$63.8M
2022 Q1
1 quarter
UNH icon
15
UnitedHealth
UNH
$365B
$124M 2.86%
242,200
-17,400
-7% -$8.74M
2021 Q4
2 quarters
ABBV icon
16
AbbVie
ABBV
$501B
$116M 2.65%
755,000
-711,100
-49% -$109M
2019 Q4
10 quarters
SNDX icon
17
Syndax Pharmaceuticals
SNDX
$1.22B
$105M 2.41%
5,450,000
+626,600
+13% +$10.4M
2020 Q2
8 quarters
CTLT icon
18
DELISTED
CATALENT, INC.
CTLT
$102M 2.35%
955,000
+173,000
+22% +$17.6M
2020 Q3
7 quarters
ZNTL icon
19
Zentalis Pharmaceuticals
ZNTL
$212M
$101M 2.31%
3,585,881
+408,882
+13% +$10.8M
2020 Q2
8 quarters
SGEN
20
DELISTED
Seagen Inc. Common Stock
SGEN
$97.3M 2.23%
550,000
+450,000
+450% +$64.8M
2021 Q1
5 quarters
BSX icon
21
Boston Scientific
BSX
$64B
$94.1M 2.16%
2,525,000
+1,328,900
+111% +$54.1M
2022 Q1
1 quarter
BIIB icon
22
Biogen
BIIB
$34.8B
$89.8M 2.06%
440,566
+75,566
+21% +$15.4M
2022 Q1
1 quarter
RARE icon
23
Ultragenyx Pharmaceutical
RARE
$1.5B
$88.3M 2.03%
1,479,500
+610,500
+70% +$37.6M
2021 Q3
3 quarters
ACHC icon
24
Acadia Healthcare
ACHC
$2.89B
$70M 1.61%
+1,035,000
New +$72.2M
2022 Q2
0 quarters
NTLA icon
25
Intellia Therapeutics
NTLA
$1.59B
$58.2M 1.34%
1,125,194
+735,119
+188% +$37.3M
2022 Q1
1 quarter
1
2 3 4 5

Similar funds

ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return
PWS
Proactive Wealth Strategies Marietta, Georgia $623M AUM 30.7% 1-Year Est. Return
LWP
LMG Wealth Partners Shreveport, Louisiana $626M AUM 36.27% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return

Avidity Partners Management's Q2 2022 Portfolio in Review

As of Q2 2022, Avidity Partners Management held 102 positions worth $4.36B, down 9.3% from $4.8B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Avidity Partners Management's Q2 2022 filing shows 10 new, 31 increased, 13 reduced and 20 closed positions. Its largest new stake was Eli Lilly: 610,000 shares worth $198M. The largest sale was Merck, an estimated $194M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 92% a quarter earlier, followed by Miscellaneous and Financials.

  • Avidity Partners Management's largest Q2 2022 buy was Eli Lilly: 610,000 shares worth $198M.
  • Avidity Partners Management added most to argenx in Q2 2022, an estimated $128M increase.
  • Avidity Partners Management's biggest Q2 2022 reduction was AbbVie, cutting an estimated $109M.
  • Avidity Partners Management fully exited Merck in Q2 2022, selling an estimated $194M.
  • Avidity Partners Management's ten largest holdings make up 45% of its $4.36B portfolio in Q2 2022.
  • Avidity Partners Management opened 10 new positions and closed 20 in Q2 2022.
  • Avidity Partners Management's portfolio value fell 9.3% quarter-over-quarter to $4.36B.

Based on Avidity Partners Management's 13F filing for Q2 2022, filed 15 Aug 2022.